376 related articles for article (PubMed ID: 28336182)
1. Light chain amyloidosis: Where are the light chains from and how they play their pathogenic role?
Zhang C; Huang X; Li J
Blood Rev; 2017 Jul; 31(4):261-270. PubMed ID: 28336182
[TBL] [Abstract][Full Text] [Related]
2. Systemic Amyloidosis Due to Clonal Plasma Cell Diseases.
Bianchi G; Kumar S
Hematol Oncol Clin North Am; 2020 Dec; 34(6):1009-1026. PubMed ID: 33099420
[TBL] [Abstract][Full Text] [Related]
3. Diagnosis and management of systemic light chain AL amyloidosis.
Bhutani D; Lentzsch S
Pharmacol Ther; 2020 Oct; 214():107612. PubMed ID: 32562825
[TBL] [Abstract][Full Text] [Related]
4. The Process of Amyloid Formation due to Monoclonal Immunoglobulins.
Morgan GJ; Wall JS
Hematol Oncol Clin North Am; 2020 Dec; 34(6):1041-1054. PubMed ID: 33099422
[TBL] [Abstract][Full Text] [Related]
5. Proteotoxicity in cardiac amyloidosis: amyloidogenic light chains affect the levels of intracellular proteins in human heart cells.
Imperlini E; Gnecchi M; Rognoni P; Sabidò E; Ciuffreda MC; Palladini G; Espadas G; Mancuso FM; Bozzola M; Malpasso G; Valentini V; Palladini G; Orrù S; Ferraro G; Milani P; Perlini S; Salvatore F; Merlini G; Lavatelli F
Sci Rep; 2017 Nov; 7(1):15661. PubMed ID: 29142197
[TBL] [Abstract][Full Text] [Related]
6. New developments in diagnosis, risk assessment and management in systemic amyloidosis.
Vaxman I; Dispenzieri A; Muchtar E; Gertz M
Blood Rev; 2020 Mar; 40():100636. PubMed ID: 31706583
[TBL] [Abstract][Full Text] [Related]
7. Systemic Amyloidosis due to Low-Grade Lymphoma.
Wechalekar AD; Chakraborty R; Lentzsch S
Hematol Oncol Clin North Am; 2020 Dec; 34(6):1027-1039. PubMed ID: 33099421
[TBL] [Abstract][Full Text] [Related]
8. Immunoglobulin light chain amyloid aggregation.
Blancas-Mejia LM; Misra P; Dick CJ; Cooper SA; Redhage KR; Bergman MR; Jordan TL; Maar K; Ramirez-Alvarado M
Chem Commun (Camb); 2018 Sep; 54(76):10664-10674. PubMed ID: 30087961
[TBL] [Abstract][Full Text] [Related]
9. In vitro co-expression of human amyloidogenic immunoglobulin light and heavy chain proteins: a relevant cell-based model of AL amyloidosis.
Klimtchuk ES; Prokaeva TB; Spencer BH; Gursky O; Connors LH
Amyloid; 2017 Jun; 24(2):115-122. PubMed ID: 28632419
[TBL] [Abstract][Full Text] [Related]
10. In situ characterization of protein aggregates in human tissues affected by light chain amyloidosis: a FTIR microspectroscopy study.
Ami D; Lavatelli F; Rognoni P; Palladini G; Raimondi S; Giorgetti S; Monti L; Doglia SM; Natalello A; Merlini G
Sci Rep; 2016 Jul; 6():29096. PubMed ID: 27373200
[TBL] [Abstract][Full Text] [Related]
11. Supportive Care for Patients with Systemic Light Chain Amyloidosis.
Wong SW; Fogaren T
Hematol Oncol Clin North Am; 2020 Dec; 34(6):1177-1191. PubMed ID: 33099432
[TBL] [Abstract][Full Text] [Related]
12. Transcriptional heterogeneity of clonal plasma cells and immune evasion in immunoglobulin light chain amyloidosis.
Wang Y; Xu L; Liu Y; Hu Y; Shi Q; Jin L; Yang L; Wang P; Zhang K; Huang X; Ge Q; Lu J
Int J Hematol; 2021 Feb; 113(2):231-242. PubMed ID: 33040275
[TBL] [Abstract][Full Text] [Related]
13. Renal Involvement in Systemic Amyloidosis Caused by Monoclonal Immunoglobulins.
Karam S; Leung N
Hematol Oncol Clin North Am; 2020 Dec; 34(6):1069-1079. PubMed ID: 33099424
[TBL] [Abstract][Full Text] [Related]
14. Recent advances in the management of AL Amyloidosis.
Kastritis E; Dimopoulos MA
Br J Haematol; 2016 Jan; 172(2):170-86. PubMed ID: 26491974
[TBL] [Abstract][Full Text] [Related]
15. Identification of two principal amyloid-driving segments in variable domains of Ig light chains in systemic light-chain amyloidosis.
Brumshtein B; Esswein SR; Sawaya MR; Rosenberg G; Ly AT; Landau M; Eisenberg DS
J Biol Chem; 2018 Dec; 293(51):19659-19671. PubMed ID: 30355736
[TBL] [Abstract][Full Text] [Related]
16. Dissecting the Molecular Features of Systemic Light Chain (AL) Amyloidosis: Contributions from Proteomics.
Rognoni P; Mazzini G; Caminito S; Palladini G; Lavatelli F
Medicina (Kaunas); 2021 Aug; 57(9):. PubMed ID: 34577839
[TBL] [Abstract][Full Text] [Related]
17. Binding of nascent collagen by amyloidogenic light chains and amyloid fibrillogenesis in monolayers of human fibrocytes.
Harris DL; King E; Ramsland PA; Edmundson AB
J Mol Recognit; 2000; 13(4):198-212. PubMed ID: 10931557
[TBL] [Abstract][Full Text] [Related]
18. Amyloidogenic light chains impair plasma cell survival.
Pick M; Lebel E; Elgavish S; Benyamini H; Nevo Y; Hertz R; Bar-Tana J; Rognoni P; Merlini G; Gatt ME
Haematologica; 2023 Dec; 108(12):3359-3371. PubMed ID: 37381778
[TBL] [Abstract][Full Text] [Related]
19. The Ultrastructure of Tissue Damage by Amyloid Fibrils.
Koike H; Katsuno M
Molecules; 2021 Jul; 26(15):. PubMed ID: 34361762
[TBL] [Abstract][Full Text] [Related]
20. Recent advances in understanding and treating immunoglobulin light chain amyloidosis.
Badar T; D'Souza A; Hari P
F1000Res; 2018; 7():. PubMed ID: 30228867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]